Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society
Provided By PR Newswire
Last update: May 15, 2023
SAN DIEGO, May 15, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced findings from a post hoc analysis of two long-term studies (KINECT™ 3 and KINECT™ 4) of INGREZZA® (valbenazine) capsules evaluating global tardive dyskinesia (TD) improvement and stability of psychiatric symptoms in adults with TD and schizophrenia or schizoaffective disorder. The data (Poster #SA135) was presented at the Schizophrenia International Research Society (SIRS) 2023 Annual Congress in Toronto, Canada.
Read more at prnewswire.comNASDAQ:NBIX (5/13/2025, 11:21:09 AM)
117.58
-2.85 (-2.37%)
Find more stocks in the Stock Screener
NBIX Latest News and Analysis
8 days ago - ChartmillTop movers in Monday's after hours sessionLet's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
8 days ago - ChartmillNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is not too expensive for the growth it is showing.Discover NEUROCRINE BIOSCIENCES INC, an undervalued growth gem. NASDAQ:NBIX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
